Search results for "Drug resistance"

showing 10 items of 953 documents

Identification of virulence factors and antibiotic resistance markers using bacterial genomics.

2016

International audience; In recent years, the number of multidrug-resistant bacteria has increased rapidly and several epidemics were signaled in different regions of the world. Faced with this situation that presents a major global public health concern, the development and the use of new and rapid technologies is more than urgent. The use of the next-generation sequencing platforms by microbiologists and infectious disease specialists has allowed great progress in the medical field. Here, we review the usefulness of whole-genome sequencing for the detection of virulence and antibiotic resistance associated genes.

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyVirulence Factors[SDV]Life Sciences [q-bio]030106 microbiologyVirulenceComputational biologyBiologyMicrobiology03 medical and health sciencesAntibiotic resistanceDrug Resistance Multiple BacterialmedicineHumansWhole genome sequencingBacteriaVirulence[ SDV ] Life Sciences [q-bio]business.industryBacterial genomicsPublic healthHigh-Throughput Nucleotide SequencingGenomicsbiology.organism_classification3. Good healthBiotechnology[SDV] Life Sciences [q-bio]Infectious disease (medical specialty)Spectrometry Mass Matrix-Assisted Laser Desorption-IonizationbusinessGenome BacterialBacteria
researchProduct

Global emergence of the widespread Pseudomonas aeruginosa ST235 clone

2018

Abstract Objectives Despite the non-clonal epidemic population structure of Pseudomonas aeruginosa , several multi-locus sequence types are distributed worldwide and are frequently associated with epidemics where multidrug resistance confounds treatment. ST235 is the most prevalent of these widespread clones. In this study we aimed to understand the origin of ST235 and the molecular basis for its success. Methods The genomes of 79 P. aeruginosa ST235 isolates collected worldwide over a 27-year period were examined. A phylogenetic network was built, using a Bayesian approach to find the Most Recent Common Ancestor, and we identified antibiotic resistance determinants and ST235-specific genes…

0301 basic medicineMost recent common ancestorClone (cell biology)[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.disease_causeGlobal HealthGenome[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyPrevalenceCluster Analysis[ SDV.BIBS ] Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]High-risk clonesPhylogenyComputingMilieux_MISCELLANEOUSMolecular EpidemiologyGeneral Medicine3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology[INFO.INFO-MA]Computer Science [cs]/Multiagent Systems [cs.MA][ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Pseudomonas aeruginosaEfflux[INFO.INFO-DC]Computer Science [cs]/Distributed Parallel and Cluster Computing [cs.DC]FluoroquinolonesMicrobiology (medical)Genotype030106 microbiologyEpidemic[INFO.INFO-SE]Computer Science [cs]/Software Engineering [cs.SE]BiologyBacterial resistanceMicrobiology[INFO.INFO-IU]Computer Science [cs]/Ubiquitous ComputingEvolution Molecular03 medical and health sciences[INFO.INFO-CR]Computer Science [cs]/Cryptography and Security [cs.CR]Antibiotic resistanceDrug Resistance BacterialmedicinePseudomonas InfectionsGenePseudomonas aeruginosaPathogenInternational clones[INFO.INFO-MO]Computer Science [cs]/Modeling and SimulationMultiple drug resistanceGenes Bacterial[INFO.INFO-ET]Computer Science [cs]/Emerging Technologies [cs.ET]Multilocus Sequence Typing
researchProduct

Genomic evolution of bacterial populations under coselection by antibiotics and phage

2017

Bacteria live in dynamic systems where selection pressures can alter rapidly, forcing adaptation to the prevailing conditions. In particular, bacteriophages and antibiotics of anthropogenic origin are major bacterial stressors in many environments. We previously observed that populations of the bacterium Pseudomonas fluorescens SBW25 exposed to the lytic bacteriophage SBW25Φ2 and a noninhibitive concentration of the antibiotic streptomycin (coselection) achieved higher levels of phage resistance compared to populations exposed to the phage alone. In addition, the phage became extinct under coselection while remaining present in the phage alone environment. Further, phenotypic tests indicate…

0301 basic medicineMutation rateantibiotic resistancemedicine.drug_class030106 microbiologyAntibioticsBiologyPseudomonas fluorescensmedicine.disease_causeMicrobiologyEvolution MolecularBacteriophage03 medical and health sciencesAntibiotic resistanceMutation RateDrug Resistance BacterialGeneticsmedicineBacteriophagesexperimental evolutionSelection GeneticEscherichia coliEcology Evolution Behavior and Systematics2. Zero hungerExperimental evolutionta1182biology.organism_classificationsublethal antibiotic concentrationsAnti-Bacterial AgentsPhenotypeLytic cyclephage resistanceStreptomycinta1181phage phi-2Genome BacterialBacteria
researchProduct

Cytotoxicity of 18 Cameroonian medicinal plants against drug sensitive and multi-factorial drug resistant cancer cells

2018

Abstract Ethnopharmacological relevance Cameroonian medicinal plants are traditionally used to treat many ailments, including cancer and related diseases. Cancer is characterized as a condition with complex signs and symptoms. It has been recommended that ethnopharmacological usages such as immune and skin disorders, inflammatory, infectious, parasitic and viral diseases should be taken into account when selecting plants for anticancer screenings, since these reflect disease states bearing relevance to cancer or cancer-like symptoms. Aim of the study The present study aims at investigating 20 methanol extracts from 15 Cameroonian medicinal plants on a panel of human cancer cell lines, inclu…

0301 basic medicineNaucleaCell SurvivalAntineoplastic AgentsApoptosisMagnoliopsida03 medical and health sciencesPhytomedicine0302 clinical medicineMorus mesozygiaCell Line TumorDrug DiscoverymedicineHumansCameroonMedicinal plantsErythrinaMembrane Potential MitochondrialPharmacologyPlants MedicinalbiologyTraditional medicinePlant ExtractsCancerbiology.organism_classificationmedicine.diseaseDrug Resistance Multiple030104 developmental biologyDrug Resistance NeoplasmCaspases030220 oncology & carcinogenesisvisual_artCancer cellvisual_art.visual_art_mediumBarkReactive Oxygen SpeciesJournal of Ethnopharmacology
researchProduct

Efficiency of Target Larvicides Is Conditioned by ABC-Mediated Transport in the Zoonotic Nematode Anisakis pegreffii

2018

Anisakiasis is among the most significant emerging foodborne parasitoses contracted through consumption of thermally unprocessed seafood harboring infective Anisakis species larvae. The efficacy of the currently applied anthelminthic therapy in humans and in model organisms has not proven sufficient, so alternative solutions employing natural compounds combined with chemical inhibitors should be explored. By testing toxicity of the natural monoterpenes nerolidol and farnesol and the conventional anthelminthics abamectin and levamisole in the presence/absence of MK-571 and Valspodar, which inhibit the ABC transporter proteins multidrug resistance protein (MRP-like) and P-glycoprotein (P-gp),…

0301 basic medicineNematodaAnisakis antiparasitic agents multidrug resistance proteinsAnisakiATP-binding cassette transporterAnisakiasisAnisakisMicrobiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMechanisms of ResistanceTubulinSettore AGR/20 - ZoocoltureAnimalsHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Settore BIO/06 - Anatomia Comparata E CitologiaNerolidolPharmacologybiologyAntiparasitic AgentsTransporterFarnesolbiology.organism_classificationAnisakis030104 developmental biologyInfectious DiseasesNematodechemistryLevamisole030220 oncology & carcinogenesisLarvaAbamectinATP-Binding Cassette TransportersEffluxABC transporterSesquiterpenes
researchProduct

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

2016

High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10–0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who …

0301 basic medicineOncologyAdultmedicine.medical_specialtyBevacizumabendocrine system diseasesPrognosimedicine.medical_treatmentHigh-grade serous ovarian carcinoma (HGSOC)Gene ExpressionAntineoplastic AgentsKaplan-Meier EstimateBrief Communication03 medical and health sciences0302 clinical medicineOvarian carcinomaInternal medicineObstetrics and GynaecologyMedicineHumansPlatinumAgedAurora Kinase ANeoplasm StagingGynecologyAged 80 and overOvarian NeoplasmsChemotherapyAURKAbusiness.industryObstetrics and GynecologyRetrospective cohort studyMiddle AgedPrognosisImmunohistochemistryfemale genital diseases and pregnancy complicationsCystadenocarcinoma SerousClinical trialSerous fluid030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleAurora Kinase APersonalized medicineTherapybusinessmedicine.drugJournal of Ovarian Research
researchProduct

“Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity…

2020

Simple Summary Despite the enormous advance in biomarker discovery, many potential biomarkers of drug activity are unable to satisfy the clinical need due to inadequate sensitivity and specificity. The nucleoside transporter hENT-1 has been studied as a potential biomarker to predict the effect of the widely used anticancer drug gemcitabine in pancreatic cancer. However, several studies showed controversial results regarding the predictive value of hENT-1, prompting new analyses with larger cohorts of patients and standardized methodologies. Improved insights on molecular mechanisms underlying hENT-1 expression and activity should also help in the identification of subsets of patients who a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFOLFIRINOXpancreatic cancerSettore BIO/05 - Zoologiaclinical outcomeDUCTAL ADENOCARCINOMAEquilibrative nucleoside transporter 1lcsh:RC254-282Articlehuman equilibrative nucleoside transporter 103 medical and health sciences0302 clinical medicinePancreatic cancerInternal medicinemedicine1112 Oncology and CarcinogenesisScience & Technologydrug resistanceROLESNucleoside analoguebiology1 HENT1business.industryCombination chemotherapyCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGemcitabineRegimenLEVELS PREDICT RESPONSE030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSMETASTASISbiology.proteinSURVIVALBiomarker (medicine)ADJUVANT GEMCITABINEbusinessLife Sciences & BiomedicineRESISTANCEmedicine.drug
researchProduct

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.

2017

Abstract Purpose The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. Patients and methods This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously tre…

0301 basic medicineOncologyDiarrheamedicine.medical_specialtyIndazolesCyclophosphamideMaximum Tolerated DosePlatinum CompoundsCarcinoma Ovarian EpithelialDisease-Free SurvivalPazopanib03 medical and health sciences0302 clinical medicineLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasms Glandular and EpithelialAdverse effectCyclophosphamideFatigueAgedOvarian NeoplasmsSulfonamidesLeukopeniabusiness.industryObstetrics and GynecologyLeukopeniaMiddle Agedmedicine.diseaseSurgeryRegimen030104 developmental biologyPyrimidinesOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisFallopian tube cancerFemalemedicine.symptomNeoplasm GradingNeoplasm Recurrence LocalbusinessOvarian cancerNeoplasms Cystic Mucinous and Serousmedicine.drugGynecologic oncology
researchProduct

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

2016

Abstract: Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura with a poor prognosis. The most active first-line regimens are platinum compounds and pemetrexed. There is no standard second-line treatment in MPM. Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. Unfortunately none of the explored targeted treatments can currently be recommended as routine treatment in MPM. We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance. We suggest that specific genetic markers are n…

0301 basic medicineOncologyDrugMesotheliomamedicine.medical_specialtyPathologyLung NeoplasmsSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectmedicine.medical_treatmentPleural NeoplasmsResistanceAntineoplastic AgentsTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsHumansMesotheliomaMolecular Targeted Therapymedia_commonPleural mesotheliomabusiness.industryPlatinum compoundsMesothelioma MalignantHematologymedicine.diseaseClinical trial030104 developmental biologyPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationPleuraMesothelioma; Pleura; Resistance; Targeted therapyMolecular ProfileHuman medicinebusinessmedicine.drug
researchProduct

Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.

2018

Background: Overexpression and amplification of the human epidermal growth factor receptor 2 (HER2) occur in 20% of total breast carcinomas. HER2-overexpression is implicated in disease initiation and progression and associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody, is the standard HER2-targeted therapy for early and metastatic HER2-amplified breast cancer patients. Trastuzumab has significantly increased clinical benefit in HER2+ metastatic and adjuvant settings; however, it is not effective for many patients due to primary or acquired resistance to the drug. During the last decade, many studies have revealed a number of novel molecular traits of HER2+ breast c…

0301 basic medicineOncologyDrugmedicine.medical_specialtymedicine.drug_classReceptor ErbB-2medicine.medical_treatmentmedia_common.quotation_subjectBreast NeoplasmsDiseaseMonoclonal antibodyBiochemistryTargeted therapy03 medical and health sciences0302 clinical medicineBreast cancerAcquired resistanceAntineoplastic Agents ImmunologicalTrastuzumabInternal medicineCell Line TumorDrug DiscoverymedicineBiomarkers TumorAnimalsHumansskin and connective tissue diseasesneoplasmsmedia_commonPharmacologybusiness.industryOrganic ChemistryTrastuzumabmedicine.diseaseGene Expression Regulation Neoplastic030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMolecular MedicineFemalebusinessAdjuvantmedicine.drugCurrent medicinal chemistry
researchProduct